STRATEC SE

Earnings Release • Apr 30, 2008

News Details

Corporate | 30 April 2008 12:19

STRATEC presents preliminary figures for the first quarter of 2008

STRATEC Biomedical Systems AG / Quarter Results

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

STRATEC presents preliminary figures for the first quarter of 2008

Birkenfeld, April 30, 2008

The sales and earnings figures of the STRATEC Group for the first three
months of the 2008 financial are within the range expected by the company.

The preliminary unaudited consolidated figures of the STRATEC Group
pursuant to IFRS (International Financial Reporting Standards) for the
first quarter of the 2008 financial year ending on March 31, 2008 are as
follows:

Key Figures (EUR 000s) 01.01.- 03.31.2008 01.01.- 03.31.2007 Change
Sales 13,208 15,674 -15.7%
Gross performance 14,767 16,131 -8.5%
EBITDA 2,691 3,055 -11.9%
EBIT 2,110 2,505 -15.8%
EBT 2,167 2,534 -14.5%
Consolidated net income 1,661 1,930 -13.9%
Earnings per share (EUR) 0.15 0.17 -11.8%

Including temporary employees, the STRATEC Group had a total of 264
employees as of March 31, 2008 (previous year: 246).

Even though turnover continues to rise in the regular STRATEC business and
potential production figures are not yet able to cover customer demand in
individual production lines, the side effects of an acquisition-related
temporary weakness in acceptance volumes on the part of one of our most
important customers has resulted in a consolidation of our sales and
earnings. The sustainable forecast provided to us by this customer for the
period October 2008 to September 2009 documents that this represents a
merely temporary phenomenon.

Based on this forecast, the acceptance volumes for the serial analyzer
system in the aforementioned period will significantly exceed the number of
serial analyzer systems accepted by this customer in the 2006 financial
year.

The long-term growth of our company is secured by a large number of
development and supply agreements. In particular, the development status of
existing development projects, as well as of projects currently in the
process of being initiated, indicate a positive business performance.

Hermann Leistner, Chairman of the Board of Management of STRATEC Biomedical
Systems AG: 'Individual phases of consolidation, in this case due to the
merging of business divisions at one of our customers, have only a
temporary impact on the further positive performance of our company. The
products currently in development are based on long-term agreements with
our customers. They will be in the supply phase from 2009 until at least
2017. Together with the projects we are currently negotiating with major
customers, these analyzer systems will secure STRATEC’s growth in the long
term. With its wide range of future technologies STRATEC, as a market and
innovation leader, is in a strong position to sustainably participate in
the current and future outsourcing needs and the outstanding renewal
investments of the diagnostics industry.'

STRATEC's management continues to expect to generate sales of between Euro
78 million and Euro 82 million and earnings before taxes (EBIT) of Euro
16.2 million to Euro 18.2 million in the 2008 financial year.

The extensive interim report will be available for downloading from our
internet site from around 3 p.m. on May 15, 2008.

About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs
and manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems,
in general together with their own reagents, to laboratories, blood banks
and research institutes around the world. The company develops its products
on the basis of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange and on other exchanges.

The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in
Germany, the USA, the UK, Switzerland and Romania.

Further information can be obtained from:

STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916 190
Fax: +49 7082 7916 999
E-mail: ir@stratec-biomedical.de
30.04.2008 Financial News transmitted by DGAP

---

Language: English
Issuer: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld
Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
Internet: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Stuttgart, München, Düsseldorf

End of News DGAP News-Service

---